SFA recalls imported French cheese due to possible listeria contamination
SINGAPORE - The Singapore Food Agency (SFA) has ordered the recall of an imported French cheese, Vieux Porche Buchette (200g), due to possible listeria contamination.
In a statement on Aug 13, SFA said that the French authorities had ordered the recall of the soft cheese in France as it may contain the food-borne bacteria, listeria.
'As the affected product was imported into Singapore, SFA has directed the importers, Classic Fine Foods Pte Ltd and Indoguna (Singapore) Pte Ltd, to recall the implicated products,' said SFA, adding that the recall was ongoing.
The affected batches bear a best-before date leading up to and including Aug 20, 2025.
Consuming the listeria bacterium can cause food poisoning. Signs of infection may include fever, muscle ache, nausea and diarrhoea.
SFA added that listeria can be fatal to pregnant women, infants and the immunocompromised.
Food that are at higher risk of being contaminated with listeria include unpasteurised or raw dairy products, soft cheese including those ripened by mould, refrigerated meat spread, smoked fish and ready-to-eat deli meats and sausages.
Consumers who bought the Vieux Porche Buchette product should not eat it, and those who have eaten it and have concerns about their health should seek medical advice, SFA said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
7 hours ago
- Straits Times
Gaza woman dies after humanitarian flight to Italy hospital
Sign up now: Get ST's newsletters delivered to your inbox Palestinians at a charity kitchen in Gaza City on Aug 2. ROME - A young Palestinian woman who was flown from Gaza to an Italian hospital in a severely emaciated state for treatment has died, the hospital said on Aug 16. The 20-year-old, identified by Italian media reports as Marah Abu Zuhri, arrived in Pisa on an Italian government humanitarian flight overnight Aug 13-14. The University Hospital of Pisa said she had a 'very complex clinical picture' and serious wasting, which is when a person has significant weight and muscle loss. On Aug 15, after undergoing tests and starting treatment, she died after a sudden respiratory crisis and cardiac arrest, the hospital said. The woman was flown to Italy with her mother on one of three Italian air force flights that arrived this week in Rome, Milan and Pisa, carrying a total of 31 patients and their companions. All the patients suffered from serious congenital diseases, wounds or amputations, the Italian foreign ministry said at the time. So far, more than 180 children and young people from Gaza have been brought to Italy since the war began between Israel and Hamas. Top stories Swipe. Select. Stay informed. Singapore Over 280 vapes seized, more than 640 people checked by police, HSA in anti-vape raids at nightspots Singapore SPLRT disruption: 28km of cables to be tested during off-service hours; works to end by Aug 23 Singapore First-half GDP boost likely temporary; Republic must stay relevant amid challenges: Chan Chun Sing Life Six-figure sales each durian season: Why S'pore durian sellers are now live selling on TikTok Singapore Airport-bound public bus to be fitted with luggage rack in 3-month trial: LTA Singapore 3 truck drivers injured after chain collision on ECP, including one rescued with hydraulic tools Life Meet the tutors who take O-level exams every year to create a 'war mate' bond with their students Life Pivot or perish: How Singapore restaurants are giving diners what they want The head of the Tuscany region, Mr Eugenio Giani, offered his condolences to the woman's family. The hospital did not elaborate on what caused her condition, but Italian news agencies reported that she was suffering from severe malnutrition. Humanitarian groups, UN agencies and the Palestinian militant group Hamas have warned of the risk of widespread famine in war-battered Gaza. AFP
New Paper
18 hours ago
- New Paper
HSA assessing rapid urine kits to speed up detection of etomidate in vapes
Rapid urine test kits could soon be used by the authorities to detect etomidate, an illicit substance increasingly found in vapes here. This marks another step in a recent clampdown against such vapes, known as Kpods, which have grown in appeal partly because some sellers claim the drug cannot be detected in urine. A Health Sciences Authority (HSA) spokeswoman said on Aug 7 that such claims are false. She added HSA was evaluating rapid urine test kits that could enable faster detection of etomidate use. Ways to test for etomidate in hair and using saliva are also in the works. Currently, vape pods, including those suspected to contain illicit substances such as etomidate, are tested at HSA's laboratories. They also conduct confirmation tests for etomidate in both blood and urine samples from patients admitted to hospitals. The spokeswoman added: "Our laboratory findings confirm that even trace amounts can be detected in the urine of those who are vaping etomidate." Minister for Health Ong Ye Kung said on July 20 the authorities were working to list etomidate as an illegal drug under the Misuse of Drugs Act. This came after a third of more than 100 vapes seized during enforcement operations and tested at random contained the substance. The legal update paves the way for abusers and traffickers of Kpods to face stricter punishment, such as mandatory rehabilitation and jail time for repeat offenders. Growing demand Law enforcement agencies in other countries are also finding ways to test for the illicit substance as they grapple with a growing trend of etomidate abuse. The substance, once called "space oil" in Hong Kong, has now been banned and renamed, and police there have been carrying rapid testing devices since January. The Hong Kong Free Press reported that the device can be inserted into a vape and detects the drug within 15 seconds with a 99 per cent accuracy rate. An etomidate rapid test kit used by the Hong Kong police force to detect the illicit substance in vape pods. Police there have been carrying these devices since January 2025. PHOTO: HONG KONG POLICE FORCE/X The substance emerged in the city in late 2023 and is now a scourge, with 327 etomidate abusers recorded in the first half of 2025, exceeding the 300 for the whole of 2024. Two manufacturers of etomidate rapid test kits told ST there is a growing global demand for their products. Chinese firm Hangzhou Clongene Biotech began developing urine and saliva rapid test kits two years ago in response to higher demand in China and abroad. A sales manager, who wanted to be known only as Ms Blanche, said it mainly supplies these kits to the government, hospitals and police. She told ST on Aug 12: "We received inquiries from some biopharmaceutical companies from Singapore in the past two weeks, and we are preparing samples for them to test now." Chinese firm Hangzhou Clongene Biotech began developing urine and saliva rapid test kits for etomidate two years ago in response to growing demand in China and abroad. PHOTO: HANGZHOU CLONGENE BIOTECH Mr Kutong, a technical support and market manager for Ecalbio, a Chinese company which started manufacturing such kits in 2018, said it sold 400,000 test kits in 2024, up from 300,000 in 2023 and 100,000 in 2022. He added that customers have come from the US, Canada and Russia, but not Singapore. Results in minutes The etomidate kits produced by these two companies resemble Covid-19 test kits. Urine and saliva samples can be tested on them, and results are displayed within five to 10 minutes. If etomidate is present, only the control line will become visible. A negative result is indicated by both the control and test lines becoming visible. In June, a published paper in scientific journal Dalton Transactions presented a new chromium(III) complex-based sensor which could test for etomidate. The sensor works by displaying a colour change if etomidate is present within vape liquids, and can provide accurate results within a minute, according to the research paper. The team of researchers from the Hong Kong Polytechnic University and Hong Kong Baptist University said vaping etomidate is a red-hot social issue that has led to health concerns and deaths. The researchers wrote: "A fast, sensitive and cost-effective detection tool for etomidate is urgently needed to support law enforcement."
Straits Times
18 hours ago
- Straits Times
Novo Nordisk's Wegovy gets accelerated US approval for serious liver condition
Sign up now: Get ST's newsletters delivered to your inbox The approval makes Wegovy the first GLP-1 class therapy cleared for MASH, a progressive liver condition that affects around 5 per cent of adults in the US. Novo Nordisk said on Aug 15 that the US Food and Drug Administration has granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition called metabolic dysfunction-associated steatohepatitis (MASH), strengthening its presence in the metabolic disease market. The approval makes Wegovy the first GLP-1 class therapy cleared for MASH, a progressive liver condition that affects around 5 per cent of adults in the United States, according to the American Liver Foundation. 'There really (have) not been good treatments in this space. We're only the second FDA-approved treatment for MASH, and we really need better medications that have better overall benefit-risk profiles, that really can also prevent the progression of the disease,' Jason Brett, principal US medical head at Novo Nordisk, said in an interview with Reuters. So far, the only available FDA-approved treatment for MASH is the Madrigal Pharmaceuticals drug Rezdiffra, which was approved in 2024. The FDA's decision was based on part one of an ongoing two-part study that showed Wegovy helped improve the organ's condition in more patients with MASH and liver scarring, compared to a placebo. Novo Nordisk said the drug is now available in the United States for adults with MASH and moderate to advanced liver scarring, and is to be used alongside proper diet and exercise. 'MASH patients need access to treatments - and that really can help them, especially early - to prevent it from progressing,' Mr Brett said. 'We're doing as much as we can to work and partner with the payer community around enhancing access and reimbursement.' Top stories Swipe. Select. Stay informed. Singapore 5 new walking trails allow hikers to explore heritage sites, win FairPrice, Cold Storage vouchers World Trump advises Ukraine's Zelensky to 'make a deal' with Russia after meeting Putin World Takeaways: Warm words contrast with cold reality of no deal at Trump-Putin summit Singapore Nowhere to run: Why Singapore needs to start protecting its coasts now Life Switching careers in middle age and beyond: How these Singapore professionals did it Asia 11,000 properties without power after 4.9-magnitude quake strikes near east coast of Australia Asia Move over, Labubu – Chiikawa is the new craze in Hong Kong Life English, physics, chemistry: These tutors take O-level exams every year He did not provide any pricing details. Based on results from part one of the trial, Novo has applied this year for approval in Europe and Japan. Further results from part two of the trial are expected in 2029. Rival Eli Lilly's tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound - previously helped up to 74 per cent of patients achieve absence of MASH with no worsening of scarring in a mid-stage trial. Accelerated approvals allow the FDA to move therapies that target serious and life-threatening conditions to the market more quickly. However, such approvals have been criticised because some drugs have later been proven to be ineffective. REUTERS
